Q2 2023

Filed Aug 10, 2023 · 10-Q · 41 days after period end · 0000950170-23-041300

Q2 2023 · 10-Q

Revenue—

Net Income

-$17.65M

N/M vs Q2 2022

EPS Diluted

-$63.83

N/M vs Q2 2022

Operating Income-$18,408,000N/M

Operating Cash Flowderived-$14,715,000N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	—	$0.00	$9.42M	$8.52M
Net Income	-$17.65M	-$21.29M	-$17.66M	-$6.03M
EPS Diluted	-$63.83	-$0.61	-$0.52	-$0.19

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR